Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Genovese M, Bartok B, Pechonkina A, Kondo A, Yin Z, Gong Q, Tasset C, Takeuchi T. Atsumi T, et al. Among authors: pechonkina a. Mod Rheumatol. 2023 Jul 4;33(4):657-667. doi: 10.1093/mr/roac083. Mod Rheumatol. 2023. PMID: 35921235 Clinical Trial.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Genovese MC, Kalunian K, Walker D, Gottenberg JE, de Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sundy JS, Tanaka Y. Takeuchi T, et al. Among authors: pechonkina a. Mod Rheumatol. 2022 Jan 5;32(1):59-67. doi: 10.1080/14397595.2020.1859675. Mod Rheumatol. 2022. PMID: 33274687 Clinical Trial.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, Takeuchi T. Tanaka Y, et al. Among authors: pechonkina a. Mod Rheumatol. 2022 Feb 28;32(2):263-272. doi: 10.1093/mr/roab030. Mod Rheumatol. 2022. PMID: 34910188 Clinical Trial.
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Bartok B, Pechonkina A, Kondo A, Yin Z, Guo Y, Tasset C, Sundy JS, Takeuchi T. Atsumi T, et al. Among authors: pechonkina a. Mod Rheumatol. 2022 Feb 28;32(2):273-283. doi: 10.1093/mr/roab021. Mod Rheumatol. 2022. PMID: 34910203 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 34922366
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Ishiguro N, Tanaka Y, Matsubara T, Atsumi T, Amano K, Sugiyama E, Yamaoka K, Winthrop K, Kivitz A, Burmester GR, Gottenberg JE, Genovese MC, Matzkies F, Guo Y, Jiang D, Bartok B, Pechonkina A, Kondo A, Besuyen R, Takeuchi T. Ishiguro N, et al. Among authors: pechonkina a. Mod Rheumatol. 2023 Jan 3;33(1):64-72. doi: 10.1093/mr/roac020. Mod Rheumatol. 2023. PMID: 35365828
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Genovese M, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Gong Q, Tasset C, Takeuchi T. Tanaka Y, et al. Among authors: pechonkina a. Mod Rheumatol. 2023 Jul 4;33(4):668-679. doi: 10.1093/mr/roac084. Mod Rheumatol. 2023. PMID: 35920102 Clinical Trial.
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Combe BG, Tanaka Y, Buch MH, Nash P, Burmester GR, Kivitz AJ, Bartok B, Pechonkina A, Xia K, Emoto K, Kano S, Hendrikx TK, Landewé RBM, Aletaha D. Combe BG, et al. Among authors: pechonkina a. Rheumatol Ther. 2023 Feb;10(1):53-70. doi: 10.1007/s40744-022-00498-x. Epub 2022 Oct 9. Rheumatol Ther. 2023. PMID: 36209441 Free PMC article.
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, Jiang W, Downie B, Mathur A, Mozaffarian A, Mozaffarian N, Gottenberg JE. Price E, et al. Among authors: pechonkina a. Rheumatology (Oxford). 2022 Nov 28;61(12):4797-4808. doi: 10.1093/rheumatology/keac167. Rheumatology (Oxford). 2022. PMID: 35377447 Free PMC article. Clinical Trial.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, Pechonkina A, Mozaffarian A, Downie B, Matzkies F, Wallace D. Werth VP, et al. Among authors: pechonkina a. Rheumatology (Oxford). 2022 May 30;61(6):2413-2423. doi: 10.1093/rheumatology/keab685. Rheumatology (Oxford). 2022. PMID: 34498056 Free PMC article. Clinical Trial.
13 results